JeromeHGoldschmidtJr.MD(He/Him)

Oncology • Blacksburg, VA

Physician

Join to view full profile

Dr. Goldschmidt is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Goldschmidt's full profile

Already have an account?

Office
2600 Research Center Dr
Ste A
Blacksburg, VA 24060
Phone+1 540-381-5291

Fax+1 540-953-4506
Is this information wrong?

Education & Training

University of RochesterFellowship, Hematology and Medical Oncology, 2003 - 2005
University of RochesterFellowship, Geriatric Medicine (Internal Medicine), 2002 - 2003
University of RochesterResidency, Internal Medicine, 1999 - 2002
University of North Carolina at Chapel Hill School of MedicineClass of 1998

Certifications & Licensure

VA State Medical License 2005 - 2026
NY State Medical License 2001 - 2005
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients Start of enrollment: 2022 Apr 12
Recruiting
Phase 1, Phase 2
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2012 Oct 31
Completed
Phase 2
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Start of enrollment: 2020 Sep 29
Active, not recruiting
Phase 2

Publications & Presentations

PubMed

Outcomes for pembrolizumab stratified by pemetrexed maintenance post pembrolizumab-platinum-pemetrexed induction in metastatic non-small-cell lung cancer.
Jerome H Goldschmidt, Srinivas Annavarapu, Divea Venkatasetty, Yunfei Wang, Melissa L Santorelli, Thomas Burke, Nathan A Pennell> ;Immunotherapy. 2024 Apr 1
2 citations
Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy.
Dipti Patel-Donnelly, Timothy Larson, Ralph Boccia, Vivian J M Cline, Adrija Mamidipalli, Jingmin Liu, Alev Akyol, Yasenchak, C. A., Jonathan W Friedberg, Rodolfo Bord...> ;Blood. 2024 Feb 29
Frontline pembrolizumab monotherapy for metastatic non-small cell lung cancer with PD-L1 expression ≥50%: real-world outcomes in a US community oncology setting.
Srinivas Annavarapu, Sartaj Alam, Melissa Santorelli, Renata Eiras Martins, Shirish M Gadgeel, Pragya Rai, Jerome H Goldschmidt, Howard Jack West> ;Frontiers in Oncology. 2024 Jan 1
Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy.
Jerome Goldschmidt, Lowell Hart, Jeffrey Scott, Kristen Boykin, Ray Bailey, Trevor Heritage, Lorena Lopez-Gonzalez, Zheng-Yi Zhou, Marie Louise Edwards, Alisha Monnett...> ;Advances in Therapy. 2023 Oct 1
2 citations
Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb).
Ran Jin, Adesuwa S Ogbomo, Neil A Accortt, Lincy S Lal, Geetanjali Bishi, Darcie Sandschafer, Jerome H Goldschmidt> ;Therapeutic Advances in Medical Oncology. 2023 Jan 1
3 citations
Burden of chemotherapy-induced myelosuppression among patients with ES-SCLC in US community oncology settings.
Jerome Goldschmidt, Alisha Monnette, Ping Shi, Divea Venkatasetty, Lorena Lopez-Gonzalez, Huan Huang> ;Future Oncology. 2022 Nov 1
11 citations
Safety and Efficacy of Pembrolizumab in Combination With Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study.
Matthew H. Taylor, Courtney Betts, Lauren Maloney, Eric Nadler, Alain Algazi, Michael J. Guarino, John Nemunaitis, Antonio Jimeno, Priti Patel, Veerendra Munugalavadla...> ;Clinical Cancer Research. 2021 Dec 3
39 citations
Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, pl...
Davey B. Daniel, Vladimer Kuchava, Igor Bondarenko, Oleksandr Ivashchuk, Sreekanth Reddy, Jana Jaal, Iveta Kudaba, Lowell L. Hart, Amiran Matitashvili, Yili Pritchett,...> ;International Journal of Cancer. 2021 May 15
188 citations
Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 Trial.
Makoto Nishio, Fabrice Barlesi, Howard Jack West, Simon Ball, Rodolfo Bordoni, Manuel Cobo, Pascale Dubray Longeras, Jerome H. Goldschmidt, Silvia Novello, Francisco O...> ;Journal of Thoracic Oncology. 2021 Apr 1
31 citations
Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results f...
Jared Weiss, Jerome H. Goldschmidt, Z. Andric, Konstantin H. Dragnev, Chad Gwaltney, Konstantina Skaltsa, Yili Pritchett, Joyce M Antal, Shannon R. Morris, Davey B. Da...> ;Clinical Lung Cancer. 2021 Mar 26
22 citations
Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2)
David R. Spigel, Robert M. Jotte, John Nemunaitis, Merrill Kingman Shum, Jeffrey A. Schneider, Jerome H. Goldschmidt, Jennifer L. Eisenstein, David Berz, Lasika Senevi...> ;Journal of Thoracic Oncology. 2021 Feb 1
2 citations
The Totality of Evidence and Use of ABP 215, a Biosimilar to Bevacizumab
Jerome H. Goldschmidt, Vladimir Hanes> ;Oncology and Therapy. 2021 Jun 1
8 citations
Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients
Devchand Paul, Svetislava J. Vukelja, Frankie A. Holmes, Joanne L. Blum, Kristi McIntyre, Deborah Lindquist, Cynthia Osborne, Ines J. Sanchez, Jerome H. Goldschmidt, Y...> ;NPJ Breast Cancer. 2019 Oct 28
9 citations
Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar.
Michael Thomas, Nick Thatcher, Jerome Goldschmidt, Yuichiro Ohe, Helen J. McBride, Vladimir Hanes> ;Immunotherapy. 2019 Sep 26
1 citations
Correction: Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomi...
Nick Thatcher, Jerome H. Goldschmidt, Mike Thomas, Michael Schenker, Zhiying Pan, Luis Paz-Ares Rodriguez, Valery Breder, Gyula Ostoros, Vladimir Hanes> ;Clinical Cancer Research. 2019 May 15
41 citations
Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non–small Cell Lung Cancer (MAPLE): A Randomized, Double-...
Nick Thatcher, Jerome H. Goldschmidt, Michael Thomas, Michael Schenker, Zhiying Pan, Luis Paz-Ares Rodriguez, Valery Breder, Gyula Ostoros, Vladimir Hanes> ;Clinical Cancer Research. 2019 Jan 7
108 citations
Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study.
Shirish M. Gadgeel, Rimas V. Lukas, J. Goldschmidt, Paul Conkling, Keunchil Park, Diego Cortinovis, Filippo de Marinis, Achim Rittmeyer, Jyoti D. Patel, Joachim von Pa...> ;Lung Cancer. 2019 Feb 1
80 citations
Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study
David R. Gandara, Joachim von Pawel, Julien Mazieres, Richard Sullivan, Åslaug Helland, Ji Youn Han, Santiago Ponce Aix, Achim Rittmeyer, Fabrice Barlesi, Toshio Kubo,...> ;Journal of Thoracic Oncology. 2018 Dec 1
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez...> ;The New England journal of medicine. 2018-09-25
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S,...> ;The New England journal of medicine. 2018-06-04
90 citations
PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer
Hui Yu, Cory Batenchuk, Andrzej Badzio, Theresa A. Boyle, Piotr Czapiewski, Daniel C. Chan, Xian Lu, Dexiang Gao, Kim Ellison, Ashley Kowalewski, Christopher J. Rivard...> ;Journal of Thoracic Oncology. 2017 Jan 1
43 citations
Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with pl...
Haralambos Raftopoulos, Abderrahmane Laadem, Paul J. Hesketh, Jerome H. Goldschmidt, Nashat Gabrail, Cynthia Osborne, Muhammad Ali, Matthew L. Sherman, Ding Wang, John...> ;Supportive Care in Cancer. 2016 Apr 1
95 citations
Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older
Andres Forero-Torres, Beata Holkova, Jerome H. Goldschmidt, Robert T. Chen, Gregg Olsen, Ralph V. Boccia, Rodolfo Bordoni, Jonathan W. Friedberg, Jeff P. Sharman, Mari...> ;Blood. 2015 Dec 24
2 citations
The appropriate use of chemotherapy in older adults with colon cancer.
Jerome H. Goldschmidt> ;Journal of the American Medical Directors Association. 2004 Jan 1
Join now to see all

Press Mentions

New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)August 2nd, 2023